ArticleJournal of ovarian research2025
Smooth endoplasmic reticulum aggregates in oocytes: a comparison of progestin-primed and GnRH antagonist IVF protocols.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVitrification improves post-thawed embryo recovery and enables new strategies for in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI). Due to its convenience and efficacy, progestin-primed ovarian stimulation (PPOS) gets more attention in daily practice. However, concerns about the impact of PPOS on oocyte and embryo quality still exist. We aimed to compare the embryological and pregnancy outcomes between PPOS and gonadotropin-releasing hormone (GnRH) antagonist protocol in IVF/ICSI cases.
methodsThis was a retrospective cohort study of 545 women undergoing IVF/ICSI cycles from July 2017 to December 2018. The patients were allocated into two groups: the PPOS and GnRH antagonist group, based on 1:1 propensity score matching. In both groups, all viable embryos were cryopreserved for later transfer. The primary endpoint was the prevalence of smooth endoplasmic reticulum aggregates (SERa) in oocytes. Secondary outcomes included the cycle characteristics and pregnancy outcomes.
resultsOvarian stimulation duration and serum estradiol level on trigger day were significantly higher in the PPOS group compared to the GnRH antagonist group. The prevalence of SERa + cycles was 9.4% in our cohort (13.0% and 12.2% in the PPOS and GnRH antagonist groups, respectively, p = 0.221). There were more frozen embryos (5.3 ± 4.5 vs. 4.8 ± 4.0, p = 0.378) in the PPOS group than in the GnRH group, particularly for the subgroup of low responders (1.6 ± 1.2 vs. 1.2 ± 1.0, p = 0.043). No significant differences were observed between the groups regarding clinical pregnancy rate, miscarriage, live birth rate, and cumulative live birth rate in the following two years after oocyte retrieval.
conclusionsOur findings suggest that the PPOS protocol provides clinical benefits and safety with comparable oocyte quality and pregnancy outcomes to the GnRH antagonist protocol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.